Organon (OGN) P/E (2021 - 2026)
Organon (OGN) P/E from May 14, 2021 to Jul 21, 2026. The TTM Organon (OGN) P/E is 14.35. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Organon (OGN)
| Year | P/E | Change |
|---|---|---|
| 2026 | 14.35 | +44.68% |
| 2025 | 9.92 | +123.33% |
| 2024 | 4.44 | -29.35% |
| 2023 | 6.29 | -10.41% |
| 2022 | 7.02 | +22.77% |
| 2021 | 5.71 | N/A |
Comparison Organon (OGN) P/E with competitors
Organon (OGN) P/E is 14.35.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -29.54% |
| PFE | Pfizer Inc | 11.65 | -18.78% |
| NVO | Novo Nordisk | 11.79 | -17.82% |
| GSK | GSK Plc | 12.10 | -15.64% |
| SNY | Sanofi | 12.12 | -15.50% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -3.69% |
| BIIB | Biogen Inc | 17.41 | +21.31% |
| GILD | Gilead Sciences Inc | 17.75 | +23.67% |
| NVS | Novartis AG | 21.60 | +50.52% |
| JNJ | Johnson & Johnson | 22.09 | +53.94% |
| AMGN | AMGEN Inc | 24.75 | +72.50% |
| MRK | Merck & Co Inc | 26.93 | +87.67% |
| AZN | Astrazeneca plc | 28.44 | +98.23% |
| LLY | Lilly(Eli) & Company | 48.44 | +237.62% |
| ABBV | Abbvie Inc | 139.08 | +869.32% |